Drug application
TAFINLAR (DABRAFENIB MESYLATE)
Drugs@FDA NDA 217514 · NOVARTIS
Key facts
| Drug name | TAFINLAR |
|---|---|
| Active ingredients | DABRAFENIB MESYLATE |
| Application type | NDA |
| Application number | 217514 |
| Company | NOVARTIS |
| Dosage forms | TABLET, FOR SUSPENSION, ORAL |
| Strength | EQ 10MG BASE |
| Marketing status | Prescription |
| Reference listed drug | Yes |
| Latest submission class | New Combination and New Formulation or New Manufacturer |
| Latest submission status date | Mar 16, 2023 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: